5|24|11 Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5|24|11 Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis 6|19|10 Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes 8|5|09 Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis 3|24|09 Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 11|20|08 Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 6|9|08 Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions 4|2|08 Radius Completes Enrollment of Phase 2 Clinical Trial of BA058 for Osteoporosis 1|30|08 Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes Press Releases 2005-2007 >
© 2011 Radius Health, Inc. | Privacy Policy | Home | Contact
201 Broadway, 6th Floor, Cambridge, MA 02139 Tel: (617) 551-4700 | Fax: (617) 551-4701
